Reports of Ambrosia restarting its young-plasma business date to 2019; they do not establish that the service operates today. The available current evidence does not settle whether that specific business reopened again or remains active. Separately, the FDA says young-donor plasma has not been approved for anti-aging or other wellness and disease-treatment claims.
Did Ambrosia really reopen its young-plasma business, and is it still operating?
The “re-opens” claim appears to refer to 2019 reporting that Ambrosia resumed operations after an FDA warning. Later blood-industry memos relay that reporting and say the business subsequently ceased operations again. Because those accounts are secondary summaries, they do not establish the details of the restart or the company’s present status.
No current primary source located for this article confirms that the plasma-infusion service reopened again or operates now. An FDA blood-establishment database search also did not identify a current Ambrosia plasma-infusion establishment, but that search result alone cannot prove the business is not operating.
There is also a naming trap: the current website for Ambrosia Biosciences describes a drug-discovery company developing oral small-molecule therapies for obesity and metabolic disorders. Available evidence does not establish that it is the same entity as the young-plasma infusion business.
Do these 3 things before closing this tab:
1Clear out junk files and repair common Windows errors2Scan for outdated or missing drivers - takes under a minute3Repair Windows errors before they cause bigger problems#1 Best Overall
Is young-donor plasma FDA-approved for wellness or disease treatment?
No. In its December 6, 2024 update, the FDA said it has not approved young-donor plasma for wellness or disease-treatment claims, including anti-aging, memory-loss prevention, dementia, Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, heart disease, or PTSD. The agency said: “We are not aware of evidence that demonstrates effectiveness for these uses.”
The FDA described establishments charging up to thousands of dollars per infusion, without specifying a single fixed price. That figure describes charges reported by the agency, not a verified Ambrosia price or a current quote.
Rank #2
- Ideal for Gifting
- Ideal for a bookworm
- Compact for travelling
Registration and trial listings are not approval
FDA establishment registration or a database listing does not mean the agency has approved a treatment use. Nor does a ClinicalTrials.gov entry, by itself, show that a treatment is approved or that applicable research requirements have been met. The FDA’s blood-establishment database is a resource for checking establishments and status, not proof that a particular service is authorized for a particular claim.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.How commercial infusions differ from accepted plasma transfusions
Plasma is a blood component used in defined clinical circumstances. The FDA refers clinicians to the June 2024 Circular of Information for accepted blood-component labeling and use information. Its examples include replacing multiple coagulation factors for certain bleeding or preoperative patients, treating selected coagulation-factor deficiencies when a specific concentrate is unavailable, and plasma exchange for thrombotic thrombocytopenic purpura.
| Question | Medically indicated plasma transfusion | Commercial young-donor infusion for wellness or disease claims |
|---|---|---|
| Indication | Specified clinical uses, such as selected coagulation-factor replacement or plasma exchange, as described in the June 2024 Circular of Information. | Claims such as anti-aging or preventing memory loss are not FDA-approved uses. |
| Evidence of benefit | Use is tied to recognized transfusion indications. | The FDA says it is unaware of evidence demonstrating effectiveness for the wellness and disease-treatment claims it discusses. |
| FDA status and oversight | Use follows applicable transfusion standards and the relevant clinical indication. | For indications outside those in the Circular, FDA says administration must be conducted by a qualified investigator or sponsor with an active FDA Investigational New Drug application. |
| Risks | Transfusion risks still apply and must be considered in care. | Risks include infectious-disease transmission, allergic reactions, and respiratory complications; a wellness claim does not remove them. |
The FDA’s Blood & Blood Products overview explains the agency’s oversight of blood collection, blood components, transfusion products, collection containers, and cell-separation devices. That general oversight information does not show that a particular Ambrosia service was licensed or approved.
Quick Recap
Best Value
- It can be a gift option
- Comes with secure packaging
- Helpful in various ways
Rank #4
What to check before paying for an infusion
- Ask what specific medical indication the provider says the plasma is intended to address, and whether that use appears among accepted transfusion indications.
- Ask whether the treatment is part of research conducted under an active FDA Investigational New Drug application with a qualified investigator or sponsor when the use falls outside the accepted indications.
- Do not rely on a registration, database listing, or ClinicalTrials.gov record as proof that the FDA approved the claimed benefit.
- Discuss transfusion risks with a qualified clinician before proceeding, especially when the proposed benefit is not established.
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
